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Effect of bisphosphonate on
temporomandibular joint in osteopenia-
induced rats by botulinum toxin A injection
on masticatory muscle: a preliminary study
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Abstract
Background: Botulinum toxin injection on the masticatory muscle induces the osteopenic condition on the
ipsilateral condyle. Bisphosphonate suppresses bone resorption and is used to treat osteopenic or osteoporotic
condition. This study aimed to evaluate the effect of bisphosphonate administration on prevention of condylar
resorption and botulinum toxin A-induced disuse osteopenia in rats.
Results: The volume of the condyle and bone volume/tissue volume (BV/TV, %) showed a strong tendency
towards statistical significance (p = 0.052 and 0.058). Trabecular thickness (Tb.Th, mm) and trabecular number (Tb.N,
1/mm) were significantly smaller in the Botox group than in the other groups (p < 0.05). The volume of the condyle
and BV/TV in the bisphosphonate 100 and bisphosphonate 200 groups showed similar values when compared with
the control group.
Conclusion: Bisphosphonate administration after botulinum toxin A injection in the masticatory muscles appears to
prevent condyle resorption and botulinum toxin-induced disuse osteopenia in rats.
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Background
Botulinum toxin causes transient paralysis of muscles by
blocking acetylcholine release at the neuromuscular
junction [1]. Botulinum toxin A (BTX-A) is most widely
used among the seven types of toxins produced by Clos-
tridium species [2]. BTX-A is used for cosmetic purpose
in patients with masseter muscle hypertrophy [3]. In
addition, BTX-A is used for reducing pain in temporo-
mandibular disorders [4].
Tsai et al. reported that a decrease in muscle volume
leads to a decrease in mandibular bone mass [5]. An ex-
perimental study on rabbits reported significant decrease
in bone quality and quantity in the condylar head at 4
weeks after botulinum toxin injection (BTI). Although
functional parameters reverted to near pre-injection
level at 12 weeks after BTI, the muscle (masseter)
remained atrophic and percentage of bone area in the
condylar head was low [6].
Bisphosphonates (BPs) suppress bone resorption
through various mechanisms such as decrease in turn-
over rate, inhibition of activity, and induction of apop-
tosis of osteoclasts [7, 8]. In this regard, BPs have been
used for the prevention of osteoporosis, bone metastasis
of malignant tumor, and pathologic fracture.
Thus, we hypothesized that the application of bisphos-
phonate after BTX-A (injected to unilateral masticatory
muscles) could contribute to the inhibition of bone re-
sorption or osteopenic condition of ipsilateral condylar
through inhibition of osteoclast action. The purpose of
this study was to evaluate the effect of bisphosphonate ad-
ministration on the prevention of condylar resorption and
botulinum toxin A-induced disuse osteopenia in rats.
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Methods
Animal model and study design (Fig. 1)
Sixteen female Sprague-Dawley (SD) rats (Orientbio Co.
Ltd., Seongnam-si, Gyenggi-do, Korea) were used in the
present study. All rats were 10-week-old of age. Two rats
were housed per cage and were individually marked. The
cages were placed in a room with filtered air at a
temperature of 22 °C ± 2 °C and 50% ± 10% relative hu-
midity. A 12-h light/dark cycle was maintained. The ani-
mals were fed a normal rodent diet and water ad libitum.
Animals were acclimated for 1 week prior to the beginning
of the study. This study was approved by and performed
in accordance with the guidelines of the institutional ani-
mal research ethics committee (IACUC No. 2017-0083).
The animals were randomly divided into four groups:
control, Botox (BTX), bisphosphonate 100 (BP100), and
bisphosphonate 200 (BP200) (n = 4). In the first and third
week, 3.75 U of botulinum toxin injection (BTI) (Botulax®,
Botulinum toxin A, HUGEL, Chuncheon, Korea) was ad-
ministered on the left side of the masseter (2.5 U) and tem-
poralis muscles (1.25U) in all groups except the control
group under general anesthesia with isoflurane. In the con-
trol group, same dosage of normal saline was administered
on the left side of the masseter and temporalis muscles.
A total of 100 μg/kg (for BP100 group) or 200 μg/kg
(for BP200 group) of zoledronic acid (ZA, Zometa
ready®, Novartis, Switzerland) was injected into the peri-
toneum, for 2 weeks after injection of BTI (in fourth and
fifth week of experiment). There was a 1-week waiting
period (sixth week) for the effect of administered bis-
phosphonate. All the animals were euthanized when the
seventh week of experiment began.
Microscopic computed tomography
Microscopic computed tomographic (μCT, Skyscan 1173,
Kontich, Belgium) images were scanned at 10.65-μm pixel
size at an energy level of 90 kV and evaluated using CTAn®
software (Skyscan, Kontich, Belgium).
The region of interest (ROI) was focused between 0.53
mm and 1.28mm from the most posterior margin of the
condyle. Then, a 0.32mm× 0.32-mm sized circle was set
at the center of condyle. Finally, cylindrical shape was
formed at the condyle area (0.32 mm diameter and 0.75
mm height), and this area was analyzed (Fig. 2a, b). Bone
volume/tissue volume (BV/TV, mm3), trabecular numbers
(Tb.N, 1/mm), trabecular thickness (Tb.Th, mm), and tra-
becular separation (Tb.Sp, mm) of each group were calcu-
lated by CTAn® software.
Three-dimensional image reconstruction and analysis (Fig. 3)
μCT images were converted to the Digital Imaging and
Communications in Medicine (DICOM) files using a con-
verting software (DicomCT ver 2.0, Bruker®). The 3D images
were then reconstructed and analyzed using image analysis
software (Mimics Research 21.0, Materialise, Belgium). The
threshold was set between − 500 and 750 Hounsfield Unit.
The reference points on the 3D images were defined
as follows:
(1) Sigmoid notch (P1)—the lowest point of the
sigmoid notch.
(2) Mandibular foramen (P2)—the most anterior point
of the opening of the inferior alveolar nerve canal.
(3) Condyle superior (P3)—the most superior point of
the condyle.
(4) Condyle anterior (P4)—the most anterior point of
the condyle.
(5) Condyle posterior (P5)—the most posterior point of
the condyle.
(6) Angle (P6)—the most prominent point of the
mandibular angle.
The reference planes on the 3D images were defined
as follows:
(1) Sagittal plane (plane S)—a plane passing through
P1, P2, and P6.
(2) Coronal plane (plane C)—a plane normal to the
plane S passing through P1 and P6.
Fig. 1 Experiment design. 3.75 U of botulinum toxin and the same dose of normal saline were administered in weeks 1 and 3. In weeks 4 and 5,
100 μg/kg or 200 μg/kg of bisphosphonate (zoledronic acid) was administered to the respective groups. A total of 100 μg/kg of normal saline was
administered to both the control and BTX groups. All animals were euthanized on week 7
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The volume of condyle (V_Con) is measured above the
plane S, which was calculated automatically by the analysis
software (Fig. 3). Distance and angle from P1 and P2 to
each point on the condyle (P3, P4, and P5) were mea-
sured, the values of which are summarized in Table 1.
Statistical analyses
The data were analyzed using a statistical analysis program
(SPSS 23.0, IBM, USA). μCT, the volume, and linear and
angular values were compared using Kruskal-Wallis ana-
lysis. p values < 0.05 indicated as statistically significant.
Results
One rat in the BTX and BP100 group died during the
experiment. Therefore, the analysis was performed on
three rats in the BTX and BP100 group and four rats in
the other groups.
μCT analysis (Table 2)
The BTX group had the lowest BV/TV (%), with mar-
ginal trend towards significance when compared to the
other groups (p = 0.052). However, other groups showed
similar values. Tb.Th (mm) and Tb.N (1/mm) values
Fig. 2 Range of analysis (a) and region of interest (ROI) (b). The region of interest (ROI) was focused between 0.53 and 1.28 mm from the most
posterior margin of the condyle. Then, a 0.32 mm× 0.32 mm sized circle was set at the center of the condyle. Finally, cylindrical shape was
formed at the condyle area (0.32 mm diameter and 0.75 mm height), and this area was analyzed
Fig. 3 Reference planes (a) and reference points (b). Plane S refers to a plane passing through P1, P2, and P6. Plane C refers to a plane normal to
plane S, passing through P1 and P6. The condyle component was separated by plane C from the other part of the mandible. P1, sigmoid notch;
P2, mandibular foramen; P3, condyle superior; P4, condyle anterior; P5, condyle posterior; P6, angle
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were the lowest in the BTX group with statistically sig-
nificant difference (p = 0.025 and p = 0.044, respectively).
Tb.Sp (mm) was the highest in the BTX group. However,
no significant difference was observed among the four
groups (Fig. 4a–d).
Volumetric, linear, and angular measurement (Table 3)
The volume of the condyle was the smallest in the BTX
group (7.68 ± 0.19 mm3), with at the edge of significance
when compared to the other groups (p = 0.058). The
condylar volumes were 10.44 ± 0.89 mm3, 10.58 ± 1.02
mm3, and 9.81 ± 1.03mm3 in the control, BP100, and
BP200 groups, respectively (Fig. 4e).
Among D13, D14, D15, D23, D24, and D25 (the dis-
tance from P1 (sigmoid notch) or P2 (lingula) to P3
(condyle superior), P4 (condyle anterior), and P5 (con-
dyle posterior)), only D14 and D24 showed a significant
difference (p < 0.05).
The angle between P1, P2, and P4 (Ang124) was the
largest in the BTX group (56.79 ± 6.80°) and the smallest
(43.57 ± 5.18°) in the control group (p = 0.080).
Discussion
Botulinum toxin A (BTX-A) has been used for the treat-
ment of masseter hypertrophy, masticatory myalgia, and
temporomandibular joint disorders [3, 4, 9]. Injection of
BTX-A into the masticatory muscles induces transient
muscle paralysis, which may increase the risk of reduc-
tion in bone mineral density, or “disuse atrophy” [10].
Several studies have reported on the resorption and/or
trabecular changes in the condyle [5, 9–11]. These
changes may occur in both experimental conditions and
clinical situations. In the present study, 3.75 U of botu-
linum toxin A was injected in the left masseter muscle
(2.5 U) and left temporal muscle (1.25 U) under general
anesthesia with isoflurane based on the protocol re-
ported in previous studies [9, 12].
Bisphosphonates suppress osteoclastic activity and in-
duce apoptosis of osteoclasts, thereby exerting a protective
effect on bone loss [7, 8, 13]. Several investigators reported
that BPs prevented subchondral bone loss on articulation
in experimental animal studies [14–16]. Chen et al. specif-
ically reported that the injection of BP into the temporo-
mandibular joint articulation could reduce changes in
cartilage and subchondral bone loss [16].
In this regard, the hypothesis of the present study was
that the administration of BP after botulinum toxin A
injection into masticatory muscles has a protective po-
tential in the maintenance of the volume of the condyle.
One study reported that the dose of bisphosphonate
(zoledronate) administered to prevent bone metastasis in
a patient with malignant tumor was 67 μg/kg every 4
weeks [17]. Black et al. reported an increase in bone
mineral density on yearly infusion of 5 mg zoledronic
acid by intravenous route [18]. The dose amounts to ap-
proximately 7 μg/kg/week, when converted, in a 60 kg
adult. In a study by Chen et al., which investigated the
prevention of condyle resorption in rats, 100 μg of alen-
dronate was administered at weekly intervals for 4 weeks
[16]. In the present study, 100 μg/kg (BP100 group) and
200 μg/kg (BP200 group) bisphosphonate were adminis-
tered considering (1) relatively fast bone turnover rate in
rats, (2) short-term dosing period (2 weeks), and (3) in-
traperitoneal route of administration.
As a result, the volume of the condyle showed similar
values between the BP100 group (receiving 100 μg/kg)
and the BP200 group (receiving 200 μg/kg). The volume
of the condyle was the lowest in the BTX group with a
strong tendency towards statistical significance when
Table 1 Definition of the volume of condyle angle and
distance measurement
Measurements Definition
V_Con (mm3) Volume of condyle calculated above plane C
Ang123 (deg) Angle between P1, P2, and P3
Ang124 (deg) Angle between P1, P2, and P4
Ang125 (deg) Angle between P1, P2, and P5
D12 (mm) Distance between P1 and P2
D13 (mm) Distance between P1 and P3
D14 (mm) Distance between P1 and P4
D15 (mm) Distance between P1 and P5
D23 (mm) Distance between P2 and P3
D24 (mm) Distance between P2 and P4
D25 (mm) Distance between P2 and P5
V_Con volume of condyle, Ang angle, D distance, Plane C coronal plane, P1
sigmoid notch, P2 mandibular foramen, P3 condyle superior, P4 condyle
anterior, P5 condyle posterior, P6 angle
Table 2 Microscopic computed tomography (μCT) analysis of the left condyle
Control (n = 4) BTX (n = 3) BP100 (n = 3) BP200 (n = 4) p value
BV/TV (%) 83.41 ± 6.69 42.55 ± 8.94 74.66 ± 17.66 72.23 ± 11.87 0.052
Tb.Th (mm)* 0.12 ± 0.02 0.07 ± 0.00 0.09 ± 0.02 0.09 ± 0.01 0.025
Tb.N (1/mm)* 7.03 ± 0.79 6.50 ± 1.05 8.22 ± 0.47 8.07 ± 0.87 0.044
Tb.Sp (mm) 0.06 ± 0.01 0.09 ± 0.02 0.06 ± 0.02 0.08 ± 0.18 0.102
BTX botulinum toxin, BP100 100 μg/kg of bisphosphonate, BP200 200 μg/kg of bisphosphonate, BV/TV bone volume/tissue volume, Tb.Th trabecular thickness, Tb.N
trabecular number, Tb.Sp trabecular separation
*Significant difference (p < 0.05), mean ± SD
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Fig. 4 Microscopic computed tomography (μCT) analysis (a–d) and three-dimensional analysis of condylar volume (e). a Bone volume/tissue
volume (BV/TV, %) in the BTX group was the lowest with marginal trend towards significance when compared to the other groups (p = 0.052). b
Trabecular thickness (Tb.Th, mm) was the lowest in the BTX group (p = 0.025). However, significant difference was observed only between the
BTX and control groups. c Trabecular number (Tb.N, 1/mm) was the lowest in BTX. BP100 and BP200 groups showed significant higher value
compared with the BTX group. d Trabecular number (Tb.N, 1/mm) and trabecular separation (Tb.Sp, mm) showed no significant difference
among the four groups. e Volume of the condyle on three-dimensional analysis showed similar result with BV/TV (%). *Statistically significant
difference compared with the BTX group (p < 0.05)
Table 3 Volumetric, angular, and linear analysis of the left side of the mandible
Control (n = 4) BTX (n = 3) BP100 (n = 3) BP200 (n = 4) p value
V_Con (mm3) 10.44 ± 0.89 7.68 ± 0.19 10.58 ± 1.02 9.81 ± 1.03 0.058
Ang123 (deg) 63.14 ± 3.33 70.72 ± 5.07 67.86 ± 5.29 61.87 ± 4.57 0.123
Ang124 (deg) 43.57 ± 5.18 56.79 ± 6.80 53.01 ± 4.41 47.09 ± 4.82 0.080
Ang125 (deg) 80.93 ± 5.62 84.71 ± 6.31 87.23 ± 6.00 80.48 ± 4.26 0.473
D12 (mm) 3.98 ± 0.08 3.86 ± 0.33 3.67 ± 0.30 3.83 ± 0.17 0.454
D13 (mm) 6.57 ± 0.07 7.10 ± 0.54 7.00 ± 0.30 6.58 ± 0.23 0.073
D14 (mm)* 3.66 ± 0.40 5.11 ± 0.57 4.74 ± 0.22 4.34 ± 0.32 0.014
D15 (mm) 7.14 ± 0.18 7.72 ± 0.48 7.56 ± 0.37 7.33 ± 0.35 0.158
D23 (mm) 7.33 ± 0.31 7.34 ± 0.24 7.49 ± 0.12 7.44 ± 0.10 0.564
D24 (mm)* 5.30 ± 0.21 6.04 ± 0.12 5.92 ± 0.18 5.92 ± 0.07 0.026
D25 (mm) 6.60 ± 0.29 7.03 ± 0.10 6.78 ± 0.09 6.92 ± 0.21 0.064
BTX botulinum toxin, BP100 100 μg/kg of bisphosphonate, BP200 200 μg/kg of bisphosphonate, V_Con volume of condyle, Ang angle, D distance
*Significant difference (p < 0.05), mean ± SD
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compared with other groups (p = 0.058). In the μCT ana-
lysis, the BV/TV of BTX group also showed the lowest
value with a strong tendency towards statistical signifi-
cance compared with the other three groups (p = 0.052).
Both cortical bone thickness and trabecular bone area
decreased after the injection of botulinum toxin into the
masticatory muscles [1, 5]. Kün-Darbois et al. also re-
ported a significant decrease in bone area/tissue area
(B.Ar/T.Ar) on trabecular bone after the injection of
botulinum toxin compared with the control group in
μCT analysis [9]. Recently, Vegger et al. reported that in-
jection of 100 μg/kg zoledronic acid via the subcutane-
ous route prevented disuse osteopenia induced by
botulinum toxin. Although the study focused on the
limb and not the condyle, our group hypothesizes a
similar effect on the temporomandibular joint [19].
Further studies with larger sample sizes are required
to establish the preventive effect of bisphosphonate on
disuse osteopenia and condylar resorption.
Conclusion
The result of the present study suggests that bisphospho-
nate administration after botulinum toxin A injection into
the masticatory muscle may have a preventive effect on
condyle resorption and botulinum toxin-induced disuse
osteopenia in rats. However, the finding of this study is
preliminary and requires further evaluation.
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